Look back at pharma news in week to February 1

3 February 2019

By Barbara Obstoj-Cardwell

New clinical trial data featured in the news last week, with Alexion presenting positive Phase III results for its Ultomiris, a follow-on to its current best seller Solaris, and Takeda released encouraging Phase III data on its dengue fever candidate TAK-003. However, another potential Alzheimer’s treatment hit the dust as Roche and AC Immune said they would discontinue development of crenezumab. Deal-making stories included Neurocrine Biosciences entering a strategic collaboration with Voyager Therapeutics on VY-AADC and VY-FXN01 for Parkinson’s disease and Friedreich’s ataxia in an up to $1.7 billion deal.

Ultomiris broadens scope with positive sHUS results

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK